December 1st, 2014
Selections from Richard Lehman’s Literature Review: December 1st
Richard Lehman, BM, BCh, MRCGP
This week’s topics include atenolol vs. losartan in children and young adults with Marfan’s syndrome, the Japanese Primary Prevention Project, and more.
NEJM — Recent Cardiology Articles- Prescription without Precision — Dangers of Dosing on the Basis of Race as Biology June 6, 2026Despite recognition that racial and ethnic categories are poor proxies for genetic diversity, race is still used to guide pharmaceutical use, posing risks of ineffectively low or dangerously high dosing.
- Finerenone in Persons with Chronic Kidney Disease without Diabetes June 4, 2026In adults without diabetes who had chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist finerenone led to a slower decrease in the estimate glomerular filtration rate than placebo over 32 months.
- Intention to Treat — Season 2: The Race Equation: BiDil — The Story of the Black Pill — ITT Episode 2.5 June 4, 2026How did a drug for congestive heart failure get approved and marketed for Black people only?
- Left Atrial Appendage Closure — Should Recommendations Be Expanded? June 4, 2026Owing to the fact that most thromboembolic complications that are attributed to atrial fibrillation originate in the left atrial appendage,1 therapies targeting the anatomical structure that might spare systemic harms are theoretically attractive. Randomized trials of left atrial appendage closure previously garnered an American College of Cardiology–American Heart...
- Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation June 4, 2026In patients with atrial fibrillation, left atrial appendage closure was noninferior to NOACs in an analysis of death from cardiovascular causes, stroke, or systemic embolism and was superior for non–procedure-related bleeding.
- Prescription without Precision — Dangers of Dosing on the Basis of Race as Biology June 6, 2026